Search Results

11 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 28 (also presented at TSRC 2017)

    Nicotine pharmacokinetics of electronic cigarettes: experimental data and a review of the literature

    FEARON I.M.(1); ELDRIDGE A.(1); GALE N.(1); McEWAN M.(1); NELSON P.(2); ROUND E.(2); STILES M.(2)
    (1) British American Tobacco (Investments) Limited, R&D, Southampton, U.K.; (2) RAI Services Co., Winston-Salem, NC, U.S.A.
    E-cigarettes are battery-powered electronic devices from which users can inhale nicotine following its aerosolisation from a heated liquid solution. Some regulators and public health bodies consider e-cigarettes as potentially playing a major role in ...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 38

    Assessing the likelihood and magnitude of a population health benefit following market introduction of a modified risk tobacco product (MRTP)

    CURTIN G.(1); SULSKY S.(2); BACHAND A.(2)
    (1) RAI Services Co., Winston-Salem, NC, U.S.A.; (2) Ramboll Environ US Corp., Amherst, MA, U.S.A.
    The evaluation and implementation of tobacco policies intended to reduce harm to the population as a whole, including tobacco users and non-users, must assess the potential for both intended and unintended consequences associated with those policies. ...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 39

    Addressing U.S. FDA’s population health standard for Camel Snus with modified risk messaging

    CURTIN G.(1); BACHAND A.(2); SULSKY S.(2); GERLACH K.(3); PILLITTERI J.(4); SHIFFMAN S.(3)
    (1) RAI Services Co., Winston-Salem, NC, U.S.A.; (2) Ramboll Environ US Corp., Amherst, MA, U.S.A.; (3) Pinney Associates, Inc., Pittsburgh, PA, U.S.A.; (4) Pinney Associates, Inc., Burlington, VT, U.S.A.
    R.J. Reynolds Tobacco Company has submitted Modified Risk Tobacco Product applications to the U.S. Food and Drug Administration seeking risk modification orders for Camel Snus advertising, which includes information that smokers who switch completely to ...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 40

    FDA’s proposed NNN product standard: review of the scientific evidence

    MARANO K.M.(1); BACHAND A.(2); LIU C.(1); SULSKY S.(2); MARIANO G.(2); CURTIN G.M.(1); PARMS T.(1); GREEN T.(3); GENTRY P.R.(3)
    (1) RAI Services Co., Winston-Salem, NC, U.S.A.; (2) Ramboll Environ US Corp., Amherst, MA, U.S.A.; (3) Ramboll Environ, Monroe, LA, U.S.A.
    The U.S. Food and Drug Administration (FDA) has published a proposed standard of 1 µg/g (dry weight) N-nitrosonornicotine (NNN) in finished smokeless tobacco products. FDA’s rationale for the standard is that NNN is a potent carcinogen, NNN is a major ...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 50 (also presented at TSRC 2017)

    Flavored e-cigarette use among U.S. adults: results from two national surveys

    SHIFFMAN S.(1,2); SEMBOWER M.(1); KIM M.(3); CURTIN G.(3)
    (1) PinneyAssociates, Inc., Pittsburgh, PA, U.S.A.; (2) University of Pittsburgh, Pittsburgh, PA, U.S.A.; (3) RAI Services Co., Winston-Salem, NC, U.S.A.
    Flavored e-cigarettes have generated much controversy and interest. To examine flavored e-cigarette use among U.S. adults, we performed analyses of two national surveys. Population Assessment of Tobacco and Health (PATH) provides a representative, ...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 51 (also presented at TSRC 2017)

    Variations in intensity of e-cigarette use, smoking history, and demographics among past-30-day e-cigarette users

    SHIFFMAN S.(1,2); SEMBOWER M.(1); KIM M.(2); CURTIN G.(2)
    (1) PinneyAssociates, Inc., Pittsburgh, PA, U.S.A.; (2) University of Pittsburgh, Pittsburgh, PA, U.S.A.; (3) RAI Services Co., Winston-Salem, NC, U.S.A.
    Analyses that examine e-cigarette use often define "users" as those with any past-30-day use; this ignores substantial variations in use patterns, and leads to incorrect perceptions of e-cigarette users. We used data from a national sample of ...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 19

    Combustible and smokeless tobacco product preparations differentially regulate calcium mobilization in the human leukemic HL60 cell line

    MAKENA P.(2); ARIMILLI S.(1); DAMRATOSKI B.E.(1); PRASAD G.L.(2)
    (1) Wake Forest University School of Medicine, Department of Microbiology & Immunology, Winston-Salem, NC, U.S.A.; (2) RAI Services Co., Winston-Salem, NC 27102, U.S.A.
    Increased calcium (Ca 2+) mobilization is central to leukocyte signaling and for regulation of immune responses. Although evidence suggests that cigarette smoking affects several biological functions including inflammatory responses, how the use of ...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 24

    FDA’s proposed N-nitrosonornicotine (NNN) Standard: epidemiological evidence

    PARMS T.(1); SULSKY S.(2); MARIANO G.(2); MARANO K.M.(1)
    RAI Services Co., Winston-Salem, NC, U.S.A.
    The U.S. Food and Drug Administration (FDA) has advanced a proposed product standard of 1 µg/g N-nitrosonornicotine (NNN) content in finished smokeless tobacco (ST) products, citing selected findings from epidemiology to support the proposed limit. The ...
  9. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 37

    FDA’s proposed NNN product standard: quantitative risk assessment

    MARANO K.M.(1); GENTRY P.R.(2); LIU C.(1)
    (1) RAI Services Co., Winston-Salem, NC, U.S.A.; (2) Ramboll Environ, Monroe, LA, U.S.A.
    The U.S. Food and Drug Administration (FDA) has published a proposed standard for N-nitrosonornicotine (NNN) content in finished smokeless tobacco products. The proposed NNN limit of 1 part per million (ppm) dry weight was derived based on a target excess ...